Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.66 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.66 |
| ▸ | TNF | P01375 | 2/20 | 0.59 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | IL1B | P01584 | 1/20 | 0.54 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.54 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25650308 | 1.00 | CRBN (0.66) | CRBNDDB1TNFIKZF3ALDH1A1 | |
| SCHEMBL24925487 | 0.87 | CRBN (0.69) | CRBNDDB1TNFIKZF3ALDH1A1 | |
| SCHEMBL24379097 | 0.87 | CRBN (0.69) | CRBNDDB1TNFIKZF3ALDH1A1 | |
| SCHEMBL24745183 | 0.86 | CRBN (0.65) | CRBNDDB1TNFIKZF3ALDH1A1 | |
| SCHEMBL30468711 | 0.85 | CRBN (0.66) | CRBNDDB1TNFIKZF3ALDH1A1 | |
| SCHEMBL29074089 | 0.85 | CRBN (0.66) | CRBNDDB1TNFIKZF3ALDH1A1 | |
| SCHEMBL25650417 | 0.84 | CRBN (0.62) | CRBNDDB1TNFIKZF3ALDH1A1 | |
| SCHEMBL27097400 | 0.84 | CRBN (0.56) | CRBNDDB1TNFIKZF3ALDH1A1 | |
| SCHEMBL23065987 | 0.84 | CRBN (0.61) | CRBNDDB1TNFIKZF3ALDH1A1 | |
| SCHEMBL25650304 | 0.84 | CRBN (0.61) | CRBNDDB1TNFIKZF3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10646575-B2 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190076541-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | CRBN 1/4885DDB1 218/4885TNF 4307/4885 |
| US-10646575-B2 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | CRBN 1/4885DDB1 218/4885TNF 4307/4885 |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | CRBN 1/4885DDB1 218/4885TNF 4307/4885 |
| US-20190076541-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | CRBN 1/4885DDB1 218/4885TNF 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.